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Background: Methicillin-resistant Staphylococcus aureus (MRSA) is recognized as an important cause of not only
hospital acquired pneumonia, but also non-nosocomial pneumonia. However, the risk factors for non-nosocomial
MRSA pneumonia are not clearly defined. Our objective was to identify risk factors at admission that were
associated with non-nosocomial MRSA pneumonia.
Methods: We evaluated 943 patients admitted to a university-affiliated hospital with culture-positive bacterial
pneumonia developed outside the hospital from January 2008 to December 2011. We compared the clinical
characteristics between MRSA and non-MRSA pneumonia, and identified risk factors associated with MRSA
pneumonia.
Results: Of 943 patients, MRSA was identified in 78 (8.2%). Higher mortality was observed in MRSA than in non-
MRSA patients (33.3% vs. 21.5%; P = 0.017). In a logistic regression analysis, MRSA pneumonia was observed more
frequently in patients with a previous history of MRSA infection (OR = 6.05; P < 0.001), a PSI score ≥120 (OR = 2.40;
P = 0.015), intravenous antibiotic treatment within 30 days of pneumonia (OR = 2.23; P = 0.018). By contrast, non-
MRSA pneumonia was observed more often in patients with a single infiltrate on chest radiography (OR = 0.55;
P = 0.029).
Conclusions: Anti-MRSA antibiotics could be considered in hospitalized non-nosocomial patients with several risk
factors identified herein. The presence or absence of these factors would provide useful guidance in selecting initial
empirical antibiotics.
Keywords: Pneumonia, Methicillin-resistant Staphylococcus aureus, Non-nosocomial, Risk factors, Community-
acquired pneumonia, Healthcare-associated pneumoniaBackground
Methicillin-resistant Staphylococcus aureus (MRSA) is the
major bacterial pathogen of hospital-acquired pneumonia
and ventilator-associated pneumonia, with an incidence
ranging from 20% to 40% [1,2]. However, increased out-of
-hospital services have led to the spread of MRSA beyond
the hospital, and 2.2% to 22.3% of healthcare-associated
pneumonia (HCAP) cases are caused by MRSA [3-6].
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reproduction in any medium, provided the orthought to be an uncommon pathogen, comprising
only 1–5% of cases [7-10]. Recently, the incidence of
community-associated MRSA pneumonia has increased
and it is regarded as an emerging problem [11-14].
Previous studies have reported that non-nosocomial
MRSA pneumonia, including CAP and HCAP, was
likely to be severe and life-threatening with a high mor-
tality [11-15]. Therefore, recent guidelines regarding the
treatment of non-nosocomial MRSA pneumonia have
recommended empirical therapy for MRSA in selected
patients [16-18]. However, optimal selection of such
patients was not clearly described. The lack of rapid,
sensitive, and specific diagnostic methods for MRSAd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Jung et al. BMC Infectious Diseases 2013, 13:370 Page 2 of 7
http://www.biomedcentral.com/1471-2334/13/370detection in pneumonia patients makes clinicians to ini-
tiate the antibiotics treatments empirically without any
degree of certainty. Some guidelines recommend that
patients with particular risk factors should be started
with anti-MRSA therapy; however, these recommenda-
tions are usually based on evidence from case studies or
opinions of experts, resulting in inconsistencies [11-19].
Moreover, among non-nosocomial pneumonia patients,
risk factors were primarily identified for CAP [20]; thus,
there are limited data regarding overall characteristics
and risk factors of MRSA pneumonia developed outside
a hospital.
The aims of our study were to examine the proportion
of pneumonia caused by MRSA among patients admit-
ted to the hospital and to identify risk factors for MRSA
at admission. This study may provide more clarified ap-
proaches for clinicians to predict MRSA pneumonia and
guide initial antibiotic treatment decisions.Methods
Study design and subjects
The present retrospective observational study included
patients admitted with pneumonia to Severance Hos-
pital in Seoul, South Korea between January 1, 2008 and
December 31, 2011.
All patients were hospitalized with pneumonia, aged ≥
20 years, and had culture-positive bacterial infections.
Patients were classified into either non-MRSA or MRSA
groups according to culture results.
The electronic medical records and imaging studies
were reviewed. Data on baseline demographics, clinical
manifestation, radiographic findings, and treatment out-
comes were compared between MRSA and non-MRSA
groups. Risk factors associated with MRSA pneumonia
were identified for the prediction of MRSA pneumonia.
The study protocol was approved by the Severance Insti-
tutional Review Board.Definitions
Pneumonia was defined as the presence of a new infil-
trate on chest radiography and signs or symptoms of
lower respiratory tract infection (e.g., cough, expector-
ation, and chest pain) that were not attributable to other
causes [12]. MRSA pneumonia was defined as pneumo-
nia coinciding with isolation of MRSA as the only poten-
tial pathogen.
HCAP was defined by at least one of the following cri-
teria according to American Thoracic Society (ATS) and
Infectious Disease Society of America (IDSA) guidelines:
hospitalization within 90 days before pneumonia diagno-
sis; admission from a nursing home or a long-term care
facility; infusion therapy such as intravenous antibiotics,
chemotherapy, or wound care within 30 days beforepneumonia diagnosis; and/or chronic hemodialysis or
peritoneal dialysis [17].
Immunosuppressed patients were defined as those in
at least one of the following categories: (1) daily use of
an oral corticosteroid (≥ 15 mg prednisone/day for more
than 1 month or combination therapy with low-dose ste-
roids and other immunosuppressants, including azathio-
prine, mycophenolate, cyclosporine, and methotrexate);
(2) radiation therapy or chemotherapy for malignancy
within 6 months prior to admission; (3) infection with
human immunodeficiency virus; (4) recipient of either
an organ or a bone marrow transplant; or (5) underlying
acquired immune deficiency disorder [20,21].
Microbiological studies
Pathogens from respiratory specimens (bronchoalveolar
lavage fluid, pleural effusion, lung abscess, or sputum)
and blood were investigated using standard microbio-
logical procedures. Sputum samples were cultured using
semi-quantitative methods, and an etiological diagnosis
was confirmed when a predominant microorganism was
isolated from group 5 sputum, according to Murray and
Washington’s grading system [22]. Positive blood cul-
tures were considered an etiological diagnosis if no other
infection source was evident. Positive urine antigen for
Streptococcus pneumoniae or Legionella were considered
evidence of infection. Antibodies against Mycoplasma
pneumoniae were detected by microparticle agglutin-
ation assay (MAG). High elevated titer (> 1:160) or four-
fold increase of the titer between 2–4 weeks interval is
regarded as Mycoplasma infection [23]. Organisms such
as coagulase-negative staphylococci and diphtheroids were
considered contaminants.
Statistical analysis
Categorical variables were analyzed using the χ2 test or
Fisher’s exact test. Continuous variables were analyzed
using t-test or the Mann–Whitney U test. To identify in-
dependent risk factors for MRSA pneumonia, multiva-
riate analysis using logistic regression was conducted.
Multi-collinearity of these variables was checked, and
the goodness of fit of the model was verified by the
Hosmer–Lemeshow test. The predictive value of the
risk-scoring model was evaluated using receiver operat-
ing characteristic (ROC) curve analysis. A P value less
than 0.05 was deemed to be statistically significant.
Results
Patient characteristics
Among 943 total patients, 78 (8.3%) were diagnosed
with MRSA pneumonia; the remaining 865 (91.7%)
comprised the non-MRSA group. Table 1 shows the
baseline and clinical characteristics of the MRSA and
non-MRSA groups. More patients in the MRSA group
Table 1 Characteristics of patients with MRSA and non-MRSA pneumoniaa
Characteristics
MRSA Non-MRSA
P-value
(n=78) (n=865)
Age 71.4 ± 9.3 66.0 ± 14.8 < 0.001
Male 58 (74.4) 565 (65.3) 0.106
Female 20 (25.6) 300 (34.7)
Type of pneumonia
Community acquired 21 (26.9) 475 (54.9) < 0.001
Health care associated 57 (73.1) 390 (45.1)
Underlying diseases
Diabetes mellitus 30 (38.5) 237 (27.4) 0.038
Chronic lung diseaseb 20 (25.6) 239 (27.6) 0.706
Cerebral vascular accident 22 (28.2) 162 (18.7) 0.043
Renal disease 14 (17.9) 104 (12.0) 0.13
Hypertension 44 (9.7) 408 (47.2) 0.118
Cardiovascular disease 21 (26.9) 148 (17.1) 0.03
Liver disease 6 (7.7) 50 (5.8) 0.454
Rheumatologic disease 3 (3.8) 31 (3.6) 0.756
Malignancy 36 (46.2) 303 (35.0) 0.05
Clinical manifestation and parameters
Bloody sputum 1 (1.3) 42 (4.9) 0.147
Confusion (decreased consciousness) 17 (21.8) 134 (15.5) 0.146
Shock at onset 20 (25.6) 267 (30.9) 0.337
Hypoxemiac 49 (62.8) 437 (50.5) 0.037
Acute renal failure at onset 13 (16.7) 162 (18.7) 0.654
Leukocytes /uL 12700 ± 7700 11800 ± 7300 0.341
Blood urea nitrogen > 30 mg/dL 25 (32.1) 255 (29.5) 0.634
Sodium < 130 mmol/L 15 (19.2) 132 (15.3) 0.355
pH < 7.35 7 (9) 72 (8.3) 0.843
Immunosuppressedd 24 (30.8) 215 (24.9) 0.25
MRSA history in previous 1 year 20 (25.6) 33 (3.8) < 0.001
Tube feeding 12 (15.4) 64 (7.4) 0.013
CURB65 1.94 ± 1.07 1.6 ± 1.15 0.015
Pneumonia Severity Index 144.7 ± 26.1 127.6 ± 38.4 < 0.001
Admission via ER 64 (82.1) 700 (80.9) 0.808
aData are presented as numbers (percentages) and plus-minus values are means ± standard deviation unless otherwise indicated.
bChronic lung disease includes asthma, COPD, and structural lung diseases, such as bronchiectasis and interstitial lung disease.
cPaO2 < 60 mmHg, SpO2 < 90% or need for oxygen therapy.
dImmunosuppression includes the following: (1) daily administration of systemic corticosteroids (at least 15 mg of prednisone per day for more than one month
or combination therapy with low dose corticosteroids and other immunosuppressants including azathioprine, mycophenolate, methotrexate, cyclosporine, or
cyclophosphamide); (2) seropositivity for human immunodeficiency virus; (3) received either a solid organ transplant or bone marrow transplant; (4) treated with
radiation therapy or chemotherapy for an underlying malignancy during the 6 months prior to hospital admission; (5) an underlying acquired immune
deficiency disorder.
Abbreviations: MRSA methicillin-resistant Staphylococcus aureus, ER emergency room.
Jung et al. BMC Infectious Diseases 2013, 13:370 Page 3 of 7
http://www.biomedcentral.com/1471-2334/13/370were categorized as HCAP than in the non-MRSA
group (73.1% vs. 45.1%; P < 0.001). Diabetes, cerebral
vascular accident, cardiovascular disease, and malig-
nancy as underlying disease were more common in
the MRSA group. Tube feeding, hypoxia at admission,
and a previous history of MRSA infection within 1year were more frequently observed in the MRSA
group. Disease severity was more prominent in the
MRSA group based on the CURB-65 and pneumonia
severity index (PSI). The distribution of pathogens in
non-MRSA group is presented in Table 2. Common
organisms included Pseudomonas aeruginosa (18.5%),
Table 2 Distribution of isolated pathogens in patients
with non-nosocomial pnseumoniaa
Microbes
No. of isolates
(%)
Gram-positive pathogens
MRSA 78 (8.3)
MSSA 51 (5.4)
Streptococcus pneumoniae 167 (17.7)
Gram-negative pathogens
Pseudomonas aeruginosa 175 (18.5)
Escherichia Coli 49 (5.2)
Klebsiella pneumoniae 156 (16.5)
Enterobacter species 31 (3.3)
Acinetobacter baumannii 24 (2.5)
Stenotrophomonas maltophilia 18 (1.9)
Haemophilus influenza 10 (1.1)
Moraxella catarrhalis 24 (2.5)
Othersb 25 (2.6)
Atypical pathogens
Mycoplasma pneumoniae 146 (15.5)
Legionella pneumophila 2 (0.2)
aData are presented as numbers (percentages). Multiple pathogens were
isolated in 91 patients.
bSerratia marcescens (n=12), Proteus mirabilis (n=5), Citrobacter species (n=3),
Morganella morganii (n=2), Burkholderia cepacia (n=1), Bacteroides fragilis (n=1),
Enterococcus faecalis (n=1).
Abbreviations: MRSA methicillin-resistant Staphylococcus aureus, MSSA
methicillin-sensitive Staphylococcus aureus.
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(16.5%), and Mycoplasma pneumoniae (15.5%).HCAP risk factors
Among the HCAP risk factors, recent hospitalization
was the most common risk factor in both groups
(Table 3). Patients in the MRSA group were significantly
more likely to be recently hospitalized, reside in a nurs-
ing home, or receive recent intravenous antibiotics.Table 3 Comparison of HCAP risk factors between MRSA and
Risk factors
Hospitalization for ≥ 2 d in the preceding 90d
Residence in a nursing home or extended care facility
Intravenous antibiotic treatment within 30 days
Chemotherapy within 30 days of pneumonia
Wound care within 30 days of pneumonia
Hemodialysis clinic
aData are presented as numbers (percentages) unless otherwise indicated.
Abbreviations: HCAP healthcare-associated pneumonia, MRSA methicillin-resistant SChest radiography
On the chest radiographs, multiple infiltrates were the
most common finding in the MRSA group (39.7%), and
the single infiltrate was in the non-MRSA group (52%)
(Table 4). The presence of a single infiltrate was signifi-
cantly more frequent in non-MRSA than MRSA groups
(52% vs. 35.9%; P = 0.006).
Treatment and clinical outcomes
From the first day of admission, glycopeptide antibiotics
were administered to 14 (17.9%) patients in the MRSA
group and 95 (11.0%) patients in the non-MRSA group
without a significant difference (P = 0.065). The propor-
tion of patients who were intubated was not different be-
tween the groups as well as the percentage of patients
admitted to the intensive care unit (Table 5). However,
in-hospital mortality was significantly higher in the
MRSA group than in the non-MRSA group (33.3% vs.
21.5%; P = 0.017), and the MRSA group had a longer
length of hospitalization compared with the non-MRSA
group (16.5 days vs. 11 days; P = 0.001).
Factors associated with MRSA pneumonia at admission
A multivariate analysis identified three risk factors inde-
pendently associated with MRSA pneumonia (Table 6).
A previous history of MRSA infection within 1 year had
the highest odds ratio (OR) of 6.05 (95% confidence
interval [CI], 2.99–12.22; P < 0.001). A high PSI score
(≥ 120) (OR = 2.40; 95% CI, 1.18–4.86; P = 0.015) and
recent administration of intravenous antibiotics (OR =
2.23; 95% CI, 1.15–4.32; P = 0.018) were also identified
as significant indicator of MRSA pneumonia. By con-
trast, a single infiltrate on chest radiography suggested a
significantly lower risk of MRSA pneumonia (OR =
0.55; 95% CI, 0.33–0.94; P = 0.029).
Discussion
This is the first study performing multivariate analysis to
identify risk factors for prediction of non-nosocomial
MRSA pneumonia. We found that patients presenting
with previous history of MRSA infection, PSI score ≥ 120,non-MRSA pneumoniaa
MRSA Non-MRSA P-value
50 (64.1) 313 (36.2) < 0.001
16 (20.5) 74 (8.6) 0.001
22 (28.2) 80 (9.2) <0.001
6 (7.7) 115 (13.3) 0.156
1 (1.3) 4 (0.5) 0.351
2 (2.6) 30 (3.5) 1
taphylococcus aureus.
Table 4 Chest radiograph findings of pneumonia patients
with MRSA and non-MRSAa
Chest radiograph
findings
MRSA Non-MRSA
P-value
(n=78) (n=865)
Single infiltrate 28 (35.9) 450 (52.0) 0.006
Multiple infiltrates 31 (39.7) 263 (30.4) 0.088
Diffuse bilateral infiltrates 19 (24.4) 152 (17.6) 0.136
Cavitation 1 (1.3) 11 (1.3) 1
Pleural effusion 16 (20.5) 126 (14.6) 0.16
aData are presented as numbers (percentages) unless otherwise indicated.
Abbreviation: MRSA methicillin resistant Staphylococcus aureus.
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days were at high risk of MRSA pneumonia and those
with single infiltrate on chest radiography were at low risk.
In our study, the prevalence of MRSA as the identified
etiology of non-nosocomial pneumonia was 8.3% (12.8%
for HCAP and 4.2% for CAP), which was consistent with
that in previous reports ranging from 3% to 30% for
HCAP and 0% to 15% for CAP [24]. Because our hospital,
as a large tertiary referral hospital, has many patients with
prior local hospital contact, the MRSA prevalence of
pneumonia is likely higher than what would be found in
typical community practice. Nevertheless, our results
show that MRSA is not a rare cause of CAP. The bound-
aries among hospital-acquired, healthcare-associated, and
community-acquired MRSA pneumonia are becoming
blurred because of the continuous movement of patients,
and thus infections, between the hospital and community.
The current HCAP criteria include a heterogeneous
group of patients with various backgrounds, particularly
diverse microbial etiologies [17]. Recently, the concept
of HCAP has become controversial, and several studiesTable 5 Treatment and clinical outcomes of pneumonia patie
Treatment and clinical outcomes
MRSA
(n=78)
Treatment
Intubation in ER 11 (14.1)
Intubation in overall 18 (23.1)
ICU admission via ER 11 (14.1)
ICU admission in overall 22 (28.2)
Clinical outcomes
In-hospital mortality 26 (33.3)
Days of ICU stay, median(IQR) 15.5 (11–30
Days of hospital stay, median(IQR) 16.5 (10–30
aData are presented as numbers (percentages) unless otherwise indicated.
bn = 22.
cn = 212.
Abbreviations: MRSA methicillin resistant Staphylococcus aureus, ER emergency roomsuggested that the definition of HCAP should be refined
to improve the prediction of resistant pathogens [25,26].
In the same context, risk factors for pneumonia due to
MRSA are subtly different from those for other potentially
resistant pathogens and treatment for MRSA pneumonia
is distinct from that for other drug-resistant pathogens.
Recent IDSA guidelines recommend empirically starting
antimicrobials both in cases of CAP and HCAP if certain
risk factors accompany MRSA pneumonia [27]. However,
the level of evidence supporting this recommendation is
low with varying risk factors reported [7,11,13-15,19,27].
Therefore, a specific predicting method for MRSA pneu-
monia is necessary and we investigated risk factors for
MRSA in all non-nosocomial pneumonia including risk
factors for HCAP.
Of HCAP criteria, recent hospitalization, residence in
a nursing home, chemotherapy, and dialysis were not in-
dependent risk factors for MRSA in the present study.
As a tertiary university-affiliated hospital, underlying dis-
ease of malignancy was observed in more than one-third
of both MRSA and non-MRSA groups, resulting in no
significant difference of chemotherapy. The total number
of patients on dialysis in the present study was relatively
small compared with that in previous studies, so it might
be an important risk factor for MRSA pneumonia in
other community settings.
Besides HCAP criteria, a history of MRSA infection
within 1 year and severe illness were most significant pre-
dictor of MRSA pneumonia. Known colonization or
infection with MRSA is one of the most essential risk fac-
tors in MRSA pneumonia [7,27,28]. Previous studies have
reported that patients with MRSA pneumonia tended to
be severely ill [19,27]. Although single variables related to
disease severity such as intubation, shock, and intensive
care unit admission were not significantly differentnts with MRSA and non-MRSAa
Non-MRSA
P-value
(n=865)
94 (10.9) 0.384
185 (21.4) 0.728
152 (17.6) 0.438
212 (24.5) 0.469
186 (21.5) 0.017
)b 10 (3–20)c 0.057
) 11 (6–20) 0.001
, IQR interquartile range, ICU intensive care unit.
Table 6 Multivariate analysis of risk factors for MRSA pneumonia
Risk factors Odds ratio 95% CI P-value
Age 1.02 0.99-1.04 0.135
Hospitalization for ≥ 2 days in the preceding 90 days 1.77 0.99-3.15 0.053
Residence in a nursing home or extended care facility 1.50 0.71-3.17 0.287
Intravenous antibiotic treatment within 30 days 2.23 1.15-4.32 0.018
Tube feeding 0.85 0.39-2.15 0.853
Hypoxemiaa 1.12 0.66-1.91 0.671
Single infiltrate 0.55 0.33-0.94 0.029
MRSA history in the previous 1 year 6.05 2.99-12.22 <0.001
PSI score ≥ 120 2.40 1.18-4.86 0.015
aPaO2 < 60 mmHg, SpO2 < 90%, or need for oxygen therapy.
Abbreviations: MRSA methicillin-resistant Staphylococcus aureus, PSI pneumonia severity index, CI confidence interval.
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the higher values for PSI score that represent severe
disease was associated with MRSA pneumonia. Several
studies reported multiple infiltrates on chest radiograph as
a high risk factor for MRSA pneumonia [28], but other
drug-resistant pathogens also tended to show multiple in-
filtrates. Thus, multiple infiltrates are not a distinct indi-
cator for prediction of MRSA. Instead, if the patient
presented with a single infiltrate on chest radiography,
there was a low probability for MRSA pneumonia. Al-
though an association between influenza and MRSA
pneumonia has been established in several studies [27], we
could not evaluate the relationship between them because
of the low frequency of testing for influenza infection and
a lack of data regarding a previous history of influenza.
Currently, there is no specific microbiological or sero-
logical diagnostic method to confirm MRSA infection
immediately on presentation of non-nosocomial pneu-
monia. Thus, there is a need for a distinct protocol for
an appropriate initial treatment for MRSA pneumonia.
The identified four variables are all clinical findings
available at admission and objective indices with little
potential for various interpretations. Those factors could
provide a clue for physicians regarding whether to start
anti-MRSA treatment empirically. For years, vancomycin
was the only antibiotic available for the treatment of
MRSA pneumonia [1], and linezolid is an alternative
choice achieving greater levels in lung epithelial lining
fluid than in plasma [29]. Further study is underway to
clarify which agent is more superior for the treatment of
MRSA pneumonia [1].
Rapid institution of appropriate antibiotic therapy in pa-
tients with highly suspected MRSA pneumonia is strongly
recommended according to several guidelines [1,18,27].
Delay of effective antibiotic therapy was associated with
increased mortality in patients with ventilator associated
pneumonia or septic shock [30,31]. Among the patients
with MRSA bacteremia, inappropriate empirical antibiotic
therapy and non-eradicable foci including pneumoniawere independent risk factors for mortality [32]. However,
unnecessary broad-spectrum antibiotic therapy may pro-
mote the emergence of resistant organisms in the patients
and the environment. Therefore, antibiotics de-escalation
should be considered according to patient’s clinical re-
sponse and the final results of cultures.
Our study has several limitations. First, this was a
retrospective study of patients admitted to a single cen-
ter. This center is a major, university-affiliated, tertiary
referral hospital in South Korea, implying that the study
population was relatively severely ill and had several
comorbidities. Therefore, patients in this study may not
reflect those at other institutions. Physicians should con-
sider the characteristics of their local patient population
when applying our approach at their institution. Second,
we analyzed only patients with culture-positive pneumo-
nia. Culture-negative pneumonia comprised a significant
proportion of all pneumonia cases. However, we in-
cluded only culture-positive cases because our goal was
specifically to identify MRSA risk factors. Third, a posi-
tive culture of MRSA may reflect colonization rather
than true infection for some cases although we consid-
ered MRSA as the only potential pathogen. Finally, our
sample size was limited to only 78 MRSA pneumonia
patients; however, ours is still one of the largest sample
sizes on this topic to date [7,11-15]. The prospective
study with a greater number of subjects is necessary to
improve prediction for MRSA pneumonia.
Conclusion
MRSA is distinct from other drug-resistant pathogens in
terms of disease severity and different antibiotic treat-
ment. This study identified clinical risk factors that pre-
dict MRSA in hospitalized, non-nosocomial pneumonia.
Anti-MRSA antibiotics could be considered in patients
with several risk factors identified herein until MRSA
has been excluded. The presence or absence of these fac-
tors would provide useful guidance for initial selection
of empirical antibiotics.
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